コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 gative long-term health consequences such as neurodegenerative disease.
2 prevention and therapy of cholesterol-driven neurodegenerative disease.
3 ve brain health and stave off the effects of neurodegenerative disease.
4 argets in subpopulations of individuals with neurodegenerative disease.
5 otential to protect the brain from aging and neurodegenerative disease.
6 ell known risk factor for the development of neurodegenerative disease.
7 and the contribution of its disruption to a neurodegenerative disease.
8 domains have emerged as important drivers of neurodegenerative disease.
9 l illnesses, including epilepsy, stroke, and neurodegenerative disease.
10 maging to cells and contributes to aging and neurodegenerative disease.
11 brain and has been linked to development and neurodegenerative disease.
12 te in hippocampus) and were more abundant in neurodegenerative disease.
13 associated with functional deterioration and neurodegenerative disease.
14 in lysosomal storage diseases are linked to neurodegenerative disease.
15 ly can lead to cancer, immunodeficiency, and neurodegenerative disease.
16 TD/amyotrophic lateral sclerosis spectrum of neurodegenerative disease.
17 uses leukaemic and tumoural diseases but not neurodegenerative disease.
18 egeneration after acute injury or in chronic neurodegenerative disease.
19 ally to ameliorate pathological processes in neurodegenerative disease.
20 ns afflicted with this chronic, debilitating neurodegenerative disease.
21 myotrophic lateral sclerosis (ALS) - a fatal neurodegenerative disease.
22 e-associated functional neuronal decline and neurodegenerative disease.
23 highly vulnerable to dysfunction and loss in neurodegenerative disease.
24 broader role of the innate immune system in neurodegenerative disease.
25 gest a potential link between LSD1 and human neurodegenerative disease.
26 provide early markers of onset of traumatic neurodegenerative disease.
27 OSN deficits in a rodent tauopathy model of neurodegenerative disease.
28 nectivity, which in turn could contribute to neurodegenerative disease.
29 uture interest as therapeutic strategies for neurodegenerative disease.
30 ion to the potential contribution of BMAA to neurodegenerative disease.
31 erebellar ataxia type 6 (SCA6), an inherited neurodegenerative disease.
32 diverse processes as cancer, evolution, and neurodegenerative disease.
33 ause dentatorubral-pallidoluysian atrophy, a neurodegenerative disease.
34 MAA) has been linked to several interrelated neurodegenerative diseases.
35 somal acidification in other LSDs and common neurodegenerative diseases.
36 disease-modifying treatments for adult human neurodegenerative diseases.
37 mutations in such genes are associated with neurodegenerative diseases.
38 ble roles for betaS in Parkinson's and other neurodegenerative diseases.
39 of PGRN insufficiency in the pathogenesis of neurodegenerative diseases.
40 y of amyloid fibrils and the pathogenesis of neurodegenerative diseases.
41 stress response is compromised in aging and neurodegenerative diseases.
42 geted agents for the treatment of cancer and neurodegenerative diseases.
43 icated in Parkinson's Disease (PD) and other neurodegenerative diseases.
44 s of neurons preferentially die in different neurodegenerative diseases.
45 is a promising therapeutic approach to treat neurodegenerative diseases.
46 diseases such as inflammatory disorders and neurodegenerative diseases.
47 ing the propagation of protein assemblies in neurodegenerative diseases.
48 e brain may contribute to symptoms of common neurodegenerative diseases.
49 s the increased risk of old, age-associated, neurodegenerative diseases.
50 pathological aggregates implicated in human neurodegenerative diseases.
51 tion could be widespread in neurological and neurodegenerative diseases.
52 ed in many pathologies, including cancer and neurodegenerative diseases.
53 own proteins underlies the most common human neurodegenerative diseases.
54 ial senescence may contribute to age-related neurodegenerative diseases.
55 systemic diseases, ranging from arthritis to neurodegenerative diseases.
56 ression of multiple sclerosis (MS) and other neurodegenerative diseases.
57 pave the way for investigation of a range of neurodegenerative diseases.
58 dicating that EMC dysregulation is linked to neurodegenerative diseases.
59 a promising approach for treating some human neurodegenerative diseases.
60 cations for future treatment of AD and other neurodegenerative diseases.
61 d their phosphate prodrugs as treatments for neurodegenerative diseases.
62 ew insights into the pathogenesis of several neurodegenerative diseases.
63 romise for treating many diseases, including neurodegenerative diseases.
64 ng microglia for therapeutic intervention in neurodegenerative diseases.
65 been implicated in autoimmune disorders and neurodegenerative diseases.
66 ognitive function during the early phases of neurodegenerative diseases.
67 th different morphologies characterize other neurodegenerative diseases.
68 l to explore how apoE isoforms contribute to neurodegenerative diseases.
69 common phenomenon and underlies a variety of neurodegenerative diseases.
70 arks of the pathophysiology of ALS and other neurodegenerative diseases.
71 nd sortilin has been associated with several neurodegenerative diseases.
72 s a possible cause of motivation deficits in neurodegenerative diseases.
73 rrelates with various human maladies such as neurodegenerative diseases.
74 underlie many human diseases, including many neurodegenerative diseases.
75 how autophagy may be affected in a range of neurodegenerative diseases.
76 n such equilibrium have been associated with neurodegenerative diseases.
77 utic for PSP might inform treatment of other neurodegenerative diseases.
78 aptic activities and play important roles in neurodegenerative diseases.
79 changes associated with learning, aging, and neurodegenerative diseases.
80 tau is a defining characteristic of several neurodegenerative diseases.
81 lation of tau exon 10 is sufficient to cause neurodegenerative diseases.
82 central role in the pathology of a number of neurodegenerative diseases.
83 nvasive adjuvant treatment for malignancy or neurodegenerative diseases.
84 ntial in solid and hematopoietic cancers and neurodegenerative diseases.
85 etes (T2D), ischemia-reperfusion injury, and neurodegenerative diseases.
86 urodegeneration that can be applied to other neurodegenerative diseases.
87 ing inflammation is thought to contribute to neurodegenerative diseases.
88 ess may be implicated in the pathogenesis of neurodegenerative diseases.
89 the SVZ, which has therapeutic potential in neurodegenerative diseases.
90 which may be relevant in motor function and neurodegenerative diseases.
91 thophysiological mechanism common to several neurodegenerative diseases.
92 DA receptor signaling that is common to many neurodegenerative diseases.
93 selection techniques, like the diagnosis of neurodegenerative diseases.
94 ATP8A2 deficiency causes severe neurodegenerative diseases.
95 cancer, fibrosis, immune dysregulation, and neurodegenerative diseases.
96 to be the cause of a group of rare and fatal neurodegenerative diseases.
97 of tauopathies like Alzheimer and many other neurodegenerative diseases.
98 tically linked to two common and devastating neurodegenerative diseases.
99 nction; findings that have ramifications for neurodegenerative diseases.
100 ysosomal storage disorders as well as common neurodegenerative diseases.
101 lammatory diseases, infectious diseases, and neurodegenerative diseases.
102 s for treatment of inherited early childhood neurodegenerative diseases.
103 aimed at the prevention of neuronal death in neurodegenerative diseases.
104 ligomeric conformers, characteristic of many neurodegenerative diseases.
105 el multitargeted strategies for AD and other neurodegenerative diseases.
106 3 (TDP-43) in the pathology of ALS and other neurodegenerative diseases.
107 ons in RNA exosome genes are associated with neurodegenerative diseases.
108 ial development of ASOs for the treatment of neurodegenerative diseases.
109 implications for understanding and treating neurodegenerative diseases.
110 spective to molecular-scale understanding of neurodegenerative diseases.
111 mers and fibrils is associated with multiple neurodegenerative diseases.
112 e pathological spread in tauopathy and other neurodegenerative diseases.
113 strategies to combat Alzheimer's and related neurodegenerative diseases.
114 ive smell test scores across a wide range of neurodegenerative diseases.
115 in system, all of which are affected in some neurodegenerative diseases.
116 lly toxic protein aggregates associated with neurodegenerative diseases, a high-throughput assay base
117 igases and effectors that are mutated across neurodegenerative diseases; accordingly, these conjugate
118 mpared with Con (p<0.0001), DCo (p<0.05) and neurodegenerative diseases (AD p<0.05, PD p<0.01, FTLD p
119 Huntington's disease (HD) is an inherited neurodegenerative disease affecting predominantly striat
120 de range of neurological diseases, including neurodegenerative diseases, after trauma, and after stro
121 e Sclerosis (MS), a chronic inflammatory and neurodegenerative disease, although a mechanistic basis
123 most common cause of inherited forms of the neurodegenerative disease amyotrophic lateral sclerosis
124 ational cohort comprising 3100 patients with neurodegenerative disease and 4351 healthy control subje
127 as the potential link between LSD1 and human neurodegenerative disease and find that loss of LSD1 ind
129 form efforts to better understand and manage neurodegenerative disease and other proteinopathies.
130 endrocytes and its potential impact in human neurodegenerative disease and related animal models.
131 principles established within other areas of neurodegenerative disease and the nuances of clinicopath
132 of focal axonal swellings (FAS) arising from neurodegenerative disease and/or traumatic brain injury.
134 include fibrils associated with systemic and neurodegenerative diseases and cancer, functional amyloi
137 F flux is involved in the pathophysiology of neurodegenerative diseases and cognitive impairment afte
138 ings demonstrate genetic pleiotropy in these neurodegenerative diseases and indicate that sporadic FT
139 iseases such as lysosomal storage disorders, neurodegenerative diseases and metabolic pathologies, as
140 d could offer new therapeutic approaches for neurodegenerative diseases and other chronic disorders r
141 the implications for other R-loop-associated neurodegenerative diseases and point to future therapeut
142 oadly associated with neurodevelopmental and neurodegenerative diseases and predicts increased mortal
143 euronal cell degeneration and death in human neurodegenerative diseases and provide a link between au
144 ulator of microglial functional phenotype in neurodegenerative diseases and serves as a novel target
145 ealed the coordination chemistry involved in neurodegenerative diseases and the interactions between
147 une system are observed at various stages of neurodegenerative diseases, and may not only drive disea
148 ondrial dysfunction is present in most major neurodegenerative diseases, and some studies have sugges
154 rapeutic drug targets.SIGNIFICANCE STATEMENT Neurodegenerative diseases are diagnosed definitively on
156 sis is that similar effects might be seen in neurodegenerative diseases as well as in RTT since a com
157 y occurring post-translation modification in neurodegenerative diseases as well as other pathological
158 drenoleukodystrophy is a rapidly progressive neurodegenerative disease, as devastating as childhood c
159 Additionally, these aggregates contain the neurodegenerative disease-associated proteins alpha-Synu
161 multitarget therapeutic agents for treating neurodegenerative diseases, based on conjugates of amino
162 hat genetic variants associated with risk of neurodegenerative diseases beyond frontotemporal lobar d
163 rts that tau pathology is a feature of these neurodegenerative diseases, but also that tau pathology
164 steine (Hcy) is considered a risk factor for neurodegenerative diseases, but the mechanisms remain to
165 ological oligomeric forms in different human neurodegenerative diseases by ELISA, immunohistochemistr
166 ome cases, IDPs such as the ones involved in neurodegenerative diseases can form protein aggregates a
167 tress show a significant sex bias, including neurodegenerative diseases, cancer, immune dysfunction,
171 ton's disease (HD) is a dominantly inherited neurodegenerative disease caused by an expanded CAG repe
172 taxia type 2 (SCA2) is an autosomal dominant neurodegenerative disease caused by CAG repeat expansion
173 kodystrophy (ALD) is a devastating inherited neurodegenerative disease caused by defects in the ABCD1
175 Spinocerebellar ataxia type 5 (SCA5) is a neurodegenerative disease caused by mutations in the cyt
176 type 35 (SCA35) is a rare autosomal-dominant neurodegenerative disease caused by mutations in the TGM
177 ntington's disease is a dominantly inherited neurodegenerative disease caused by the expansion of a C
178 repeat proteins, especially in age-dependent neurodegenerative diseases caused by nucleotide repeat e
181 lerosis (ALS) is a devastating and incurable neurodegenerative disease, characterised by progressive
182 eral sclerosis (ALS) is a progressive, fatal neurodegenerative disease characterized by degeneration
183 at tau-transgenic (tau-tg) mice that develop neurodegenerative disease characterized by deposition of
184 phic lateral sclerosis (ALS) is debilitating neurodegenerative disease characterized by motor neuron
185 ms of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive a
188 (TDP-43) misfolding is implicated in several neurodegenerative diseases characterized by aggregated p
189 hes the MPC as a therapeutic target to treat neurodegenerative diseases characterized by excitotoxici
190 oncussion in athletes, including risk of the neurodegenerative disease chronic traumatic encephalopat
191 dominant cause of frontotemporal dementia, a neurodegenerative disease commonly characterized by disr
192 cribe a novel microglia type associated with neurodegenerative diseases (DAM) and identify markers, s
193 ing diseases such as cardiovascular disease, neurodegenerative diseases, diabetes, obesity, and asthm
194 hondrial quality control have been linked to neurodegenerative diseases due in part to the central ro
198 c variants at the 7p21 locus and risk of the neurodegenerative disease frontotemporal lobar degenerat
199 Os are ideal candidates for the treatment of neurodegenerative diseases, given numerous advancements
201 elationship between repeated concussions and neurodegenerative disease has received significant atten
203 and PACT in inflammatory processes linked to neurodegenerative diseases has been proposed and raised
204 widely observed in tumorigenesis, ageing and neurodegenerative diseases, highlighting the importance
205 ke that of other proteins that accumulate in neurodegenerative disease, however, the function of alph
206 utic target in breast cancer and age-related neurodegenerative diseases; however, CYP27A1 inhibition
207 he CLN3 gene is the most prevalent inherited neurodegenerative disease in childhood resulting in wide
208 etch close to the C-terminus that triggers a neurodegenerative disease in humans when its length exce
210 ENT Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease in which motor neurons (MNs) i
211 Retinitis pigmentosa (RP) is an inherited neurodegenerative disease, in which the death of mutant
212 yotrophic lateral sclerosis (ALS), two major neurodegenerative diseases, in single-nucleotide polymor
213 outpatient referral center for patients with neurodegenerative diseases, included 6 3 with typical am
214 ical markers of oxidative stress, aging, and neurodegenerative diseases including Alzheimer's disease
215 tic applications using various specimens for neurodegenerative diseases including Alzheimer's disease
216 ociated protein tau is implicated in various neurodegenerative diseases including Alzheimer's disease
217 ted with a number of metabolic disorders and neurodegenerative diseases including Alzheimer's, Parkin
218 Astroglial pathology is seen in various neurodegenerative diseases including frontotemporal deme
219 and missense mutations in TFG cause several neurodegenerative diseases including hereditary motor an
220 minases have been shown to be hyperactive in neurodegenerative diseases including multiple sclerosis.
221 een linked to susceptibility for a number of neurodegenerative diseases, including AD; however, studi
222 osphorylated tau is a major hallmark of many neurodegenerative diseases, including Alzheimer disease
223 gregates found in the brain of patients with neurodegenerative diseases, including Alzheimer's and Pa
225 oduce pathological structures in a number of neurodegenerative diseases, including Alzheimer's diseas
228 resents a prevalent genetic cause of several neurodegenerative diseases, including amyotrophic latera
229 NT TDP-43 dysfunction is a common feature in neurodegenerative diseases, including amyotrophic latera
230 ysfunctional lysosomes are linked to several neurodegenerative diseases, including lysosomal storage
232 n within the brain has been observed in many neurodegenerative diseases, including prion disease.
235 alpha-Synuclein (aSyn) is the main driver of neurodegenerative diseases known as "synucleinopathies,"
236 in Parkinson's disease and in several other neurodegenerative diseases known as synucleinopathies.
237 somal storage disorders (LSDs) and to common neurodegenerative diseases like Alzheimer's and Parkinso
238 nc and iron, and oxidative stress in several neurodegenerative diseases like Alzheimer's, Parkinson's
239 in misfolding is a key pathological event in neurodegenerative diseases like prion diseases, synuclei
240 ment expression has been observed in several neurodegenerative diseases, little is known about their
242 rly detection of the behavioural deficits of neurodegenerative diseases may help to describe the path
243 ated with a number of pathologies, including neurodegenerative diseases, metabolic disorders, and can
244 etrimental functions have been documented in neurodegenerative diseases, metabolic syndrome, renal di
245 the first transgenic zebrafish model of the neurodegenerative disease MJD, and identified relevant d
246 de markers involved in many diseases such as neurodegenerative diseases, obesity, bulimia, and anorex
250 n that inflammation plays a critical role in neurodegenerative diseases of the CNS, including Alzheim
251 o history of drug abuse, psychosis, dementia/neurodegenerative diseases or medical conditions with kn
252 in tissues of the CNS and is associated with neurodegenerative disease, particularly Parkinson-like s
254 l variant frontotemporal dementia (bvFTD), a neurodegenerative disease presenting with heterogeneous
255 ouse model of Batten disease, a prototypical neurodegenerative disease presenting with intralysosomal
256 hic lateral sclerosis is a fatal adult-onset neurodegenerative disease produced by mutations in SOD1
259 ith amyotrophic lateral sclerosis who lacked neurodegenerative disease-related pathology outside of t
261 , specific contributions of BMAA toxicity to neurodegenerative diseases remain to be fully resolved.
264 multiple states of microglial activation in neurodegenerative disease settings, which might explain
267 hondrial encephalomyopathies, to age-related neurodegenerative diseases such as Alzheimer's and Parki
268 /reperfusion injury, cataract formation, and neurodegenerative diseases such as Alzheimer's disease (
269 ght underlie the progression of pathology in neurodegenerative diseases such as Alzheimer's disease,
271 nction is a common pathological component of neurodegenerative diseases such as amyotrophic lateral s
272 Prions are infectious agents that cause neurodegenerative diseases such as Creutzfeldt-Jakob dis
273 sorder of declining language associated with neurodegenerative diseases such as frontotemporal degene
274 models, KMO inhibition has shown benefit in neurodegenerative diseases such as Huntington's and Alzh
275 damage in acute neuronal injury and chronic neurodegenerative diseases such as multiple sclerosis.
276 ation of neurodevelopmental, psychiatric and neurodegenerative diseases, such as autism spectrum diso
278 eme in physiological aging and other related neurodegenerative diseases, such as Huntington's and Alz
280 ral sclerosis (ALS) is a rapidly progressing neurodegenerative disease that is characterized by motor
281 inal muscular atrophy (SMA) is a progressive neurodegenerative disease that is the leading genetic ca
282 rm encephalopathies (TSEs), which are lethal neurodegenerative diseases that affect humans and a wide
284 relevant in the context of neurological and neurodegenerative diseases that involve changes in dopam
285 preclinical onset of smell deficits in many neurodegenerative diseases, the answer to this question
287 t remains unknown why PGRN deficiency causes neurodegenerative diseases, there is increasing evidence
288 ology are affected during the progression of neurodegenerative diseases, there is no quantitative met
289 zed role of mitochondrial quality control in neurodegenerative diseases, these studies illustrate, fo
290 hiles is associated with the pathogenesis of neurodegenerative diseases, to epigenetic alterations an
292 ophic lateral sclerosis (ALS), a progressive neurodegenerative disease, we measured electromyogram (E
293 iate animal model for preclinical studies of neurodegenerative diseases where the cholinergic system
294 ential risk-increasing role across different neurodegenerative diseases, whereas the novel genetic as
296 xpression in Friedreich's ataxia, a terminal neurodegenerative disease with no effective therapy.
297 Alzheimer's disease (AD) is a detrimental neurodegenerative disease with no effective treatments.
298 pinal muscular atrophy (SMA) is a hereditary neurodegenerative disease with severity ranging from pro
299 ht on how oxidative stress can contribute to neurodegenerative disease, with unfolding, aggregation,
300 mer's disease is one of the most devastating neurodegenerative diseases without effective therapies.
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。